GRCE vs LEN · $35.0M cap vs rev $34.19B
Grace Therapeutics, Inc. (GRCE) versus LEN (LEN) — a side-by-side from cached financials, not a winner call.
Grace Therapeutics, Inc. (GRCE) is a biotechnology company listed on US.
LEN (LEN) common stock.
GRCE does not have a complete income-statement cache yet.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
GRCE currently screens at market cap $35.0M. LEN currently screens at market cap $0.
Not investment advice. Open the GRCE and LEN stock pages for the full models.
Not investment advice.